Take an integrated, multidisciplinary and intersectoral approach to address the key unresolved questions on the molecular and cellular basis of acute leukemia MRD

  • Establish a shared preclinical data platform on MRD characteristics
  • Unite key European experts to attain a critical mass in expertise and datasets
  • Develop treatment approaches improving survival outcomes and spare patients from treatments that are ultimately ineffective and toxic
  • Train the experts of tomorrow that can influence future research, trial design and medicine policy.